Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 03:53:39 2024-04-16 am EDT			5-day change	1st Jan Change
26.23 ^EUR	+3.06%		+3.66%	-6.27%

Apr. 15	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
Mar. 22	Cannabis law and clinic atlas in the Bundesrat	DP

FRESENIUS SE : JP Morgan remains its Buy rating

November 02, 2021 at 05:17 am EDT

Analyst David Adlington from JP Morgan research considers the stock attractive and recommends it with a Buy rating. The target price remains set at EUR 52.40.

Latest news about Fresenius SE & Co. KGaA

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Cannabis law and clinic atlas in the Bundesrat	Mar. 22	DP
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Criticism of hospital reform: 'Redistribution from the bottom to the top'	Mar. 20	DP
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
Doctors strike at university hospitals	Mar. 11	DP
Doctors go on warning strike at 23 university hospitals	Mar. 11	DP
FRESENIUS SE : Gets a Buy rating from Berenberg	Mar. 07	ZD
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	Mar. 06	MT
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	Mar. 05	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 05	MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon	Mar. 05	MT
Fresenius Medical Care to Sell Dialysis Clinics in Brazil, Colombia, Chile, Ecuador to DaVita	Mar. 05	MT
European Equities Traded in the US as American Depositary Receipts Decline Tuesday	Mar. 05	MT
FRESENIUS SE : Deutsche Bank remains its Buy rating	Feb. 29	ZD
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading	Feb. 26	MT
FRESENIUS SE : Receives a Buy rating from UBS	Feb. 26	ZD
FRESENIUS SE : Berenberg gives a Buy rating	Feb. 26	ZD
Berenberg: Fresenius Medical Care to Experience Solid Growth in FY24 as Demand Recovers	Feb. 22	MT
FRESENIUS SE : Barclays reaffirms its Buy rating	Feb. 22	ZD
Solution for transparency and financing at hospitals	Feb. 22	DP
FRESENIUS : A good ending does not allow for extreme optimism in 2024	Feb. 22

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.45 EUR

Average target price

36.22 EUR

Spread / Average Target

+42.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-6.27%	15.24B
CVS HEALTH CORPORATION	-12.66%	86.92B
HCA HEALTHCARE, INC.	+19.19%	85.34B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+12.75%	29.88B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-10.55%	17.1B
QUEST DIAGNOSTICS INCORPORATED	-6.70%	14.29B
EUROFINS SCIENTIFIC SE	+1.09%	12.38B
PURE HEALTH HOLDING	-30.53%	12.1B
DAVITA INC.	+24.05%	11.4B
NATERA, INC.	+44.35%	10.92B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : JP Morgan remains its Buy rating

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services